5AM Venture Management, LLC
SAN FRANCISCO, CA · CIK 1799883 · 13F filing filed 2021-08-16
SEC-registered investment adviser since 2021 · limited liability company
- Assets managed$1.1bn
- Staff32 · 18 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds12 (1 hedge) · $947.0m gross assets
- Website5amventures.com
- Form ADV · 2026-03-30SEC adviser record
- Kindhedge funds, private equity, venture, futures
- Others nearbySan Francisco, CA, Boston, MA, New York, NY
As an employer
- Offices in1 country
- Private fundsventure capital 9, private equity 2, hedge 1
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| San Francisco, CA (main office)United States | about 8 |
| Boston, MAUnited States | 7 |
| New York, NYUnited States | 3 |
US visa salary filings
- Filings FY20251
- Median salary offered$350,000
- Middle half$350,000 – $350,000
- Job titles1
| Job title | Filings | Median |
|---|---|---|
| Senior Research AnalystNew York, NY | 1 | $350,000 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: 5AM Venture Management, LLC.
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Holdings, Q2 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| VOR BIOPHARMA INC COM | $124.8m31.41% | Unchanged |
| AKOUOS INC COM | $51.9m13.06% | Unchanged |
| IDEAYA BIOSCIENCES INC IDYA | $37.7m9.50% | Unchanged |
| HOMOLOGY MEDICINES INC FIXX | $33.0m8.30% | Unchanged |
| ARVINAS INC ARVN | $30.8m7.75% | Reduced -100.0k |
| CRINETICS PHARMACEUTICALS IN CRNX | $25.7m6.46% | Unchanged |
| CABALETTA BIO INC CABA | $25.7m6.46% | Unchanged |
| IMPEL NEUROPHARMA INC COM | $25.5m6.43% | New |
| SCPHARMACEUTICALS INC SCPH | $23.4m5.89% | Unchanged |
| JANUX THERAPEUTICS INC JANX | $11.1m2.80% | New |
| CIDARA THERAPEUTICS INC COM | $4.1m1.02% | Unchanged |
| 5 01 ACQUISITION CORP COM CL A | $3.6m0.92% | Unchanged |
Sold out since Q1 2021
| Security | Value then |
|---|---|
| APREA THERAPEUTICS INC | $3.2m619.2k shares |